Search
Insilico Medicine's TNIK Inhibitor Poised for Breakthrough Therapy Inclusion
2025-04-29 /
Read about 0 minute
Author：小编
Insilico Medicine's INS018_055 tablet, tailored for the treatment of Idiopathic Pulmonary Fibrosis (IPF), has been put forward as a potential breakthrough therapy. IPF, a chronic lung condition impacting roughly 5 million individuals worldwide, currently faces a scarcity of effective treatment options. As a TNIK-targeted inhibitor, INS018_055 is advancing through Phase IIa clinical trials. These trials have demonstrated that a 60mg dose of INS018_055 can notably enhance lung function in patients, while maintaining a manageable safety profile. The primary adverse effects observed have been mild to moderate diarrhea and abnormal liver function, offering fresh hope for the treatment of IPF patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
